The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Research Report 2025
Synopsis
Neuromyelitis optica spectrum disorder (NMOSD), also known as Devic disease, is a chronic disorder of the brain and spinal cord dominated by inflammation of the optic nerve (optic neuritis) and the spinal cord (myelitis). Classically, it was felt to be a monophasic illness, consisting of episodes of inflammation of one or both optic nerves and the spinal cord over a short period of time (days or weeks) but, after the initial episode, no recurrence. It is now recognized that most patients satisfying current criteria for NMOSD experience repeated attacks separated by periods of remission. The interval between attacks may be weeks, months or years.
The global Neuromyelitis Optica Spectrum Disorder (NMOSD) market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Neuromyelitis Optica Spectrum Disorder (NMOSD) is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Neuromyelitis Optica Spectrum Disorder (NMOSD) is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Neuromyelitis Optica Spectrum Disorder (NMOSD) in Hospital is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Neuromyelitis Optica Spectrum Disorder (NMOSD) include F. Hoffmann-La Roche Ltd, Alexion Pharmaceuticals, RemeGen, Nihon Pharmaceutical, Harbour BioMed, Lundbeck, Bionure, Opexa Therapeutics and TG Therapeutics, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Neuromyelitis Optica Spectrum Disorder (NMOSD), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Neuromyelitis Optica Spectrum Disorder (NMOSD).
Report Scope
The Neuromyelitis Optica Spectrum Disorder (NMOSD) market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Neuromyelitis Optica Spectrum Disorder (NMOSD) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Neuromyelitis Optica Spectrum Disorder (NMOSD) companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
F. Hoffmann-La Roche Ltd
Alexion Pharmaceuticals
RemeGen
Nihon Pharmaceutical
Harbour BioMed
Lundbeck
Bionure
Opexa Therapeutics
TG Therapeutics
Bio-Thera Solutions
Boston Pharmaceuticals
Cour Pharmaceutical
Segment by Type
Intravenous
Oral
Subcutaneous
Others
Segment by Application
Hospital
Clinic
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Neuromyelitis Optica Spectrum Disorder (NMOSD) companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Neuromyelitis optica spectrum disorder (NMOSD), also known as Devic disease, is a chronic disorder of the brain and spinal cord dominated by inflammation of the optic nerve (optic neuritis) and the spinal cord (myelitis). Classically, it was felt to be a monophasic illness, consisting of episodes of inflammation of one or both optic nerves and the spinal cord over a short period of time (days or weeks) but, after the initial episode, no recurrence. It is now recognized that most patients satisfying current criteria for NMOSD experience repeated attacks separated by periods of remission. The interval between attacks may be weeks, months or years.
The global Neuromyelitis Optica Spectrum Disorder (NMOSD) market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Neuromyelitis Optica Spectrum Disorder (NMOSD) is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Neuromyelitis Optica Spectrum Disorder (NMOSD) is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Neuromyelitis Optica Spectrum Disorder (NMOSD) in Hospital is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Neuromyelitis Optica Spectrum Disorder (NMOSD) include F. Hoffmann-La Roche Ltd, Alexion Pharmaceuticals, RemeGen, Nihon Pharmaceutical, Harbour BioMed, Lundbeck, Bionure, Opexa Therapeutics and TG Therapeutics, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Neuromyelitis Optica Spectrum Disorder (NMOSD), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Neuromyelitis Optica Spectrum Disorder (NMOSD).
Report Scope
The Neuromyelitis Optica Spectrum Disorder (NMOSD) market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Neuromyelitis Optica Spectrum Disorder (NMOSD) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Neuromyelitis Optica Spectrum Disorder (NMOSD) companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
F. Hoffmann-La Roche Ltd
Alexion Pharmaceuticals
RemeGen
Nihon Pharmaceutical
Harbour BioMed
Lundbeck
Bionure
Opexa Therapeutics
TG Therapeutics
Bio-Thera Solutions
Boston Pharmaceuticals
Cour Pharmaceutical
Segment by Type
Intravenous
Oral
Subcutaneous
Others
Segment by Application
Hospital
Clinic
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Neuromyelitis Optica Spectrum Disorder (NMOSD) companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Intravenous
1.2.3 Oral
1.2.4 Subcutaneous
1.2.5 Others
1.3 Market by Application
1.3.1 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Perspective (2019-2030)
2.2 Neuromyelitis Optica Spectrum Disorder (NMOSD) Growth Trends by Region
2.2.1 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Neuromyelitis Optica Spectrum Disorder (NMOSD) Historic Market Size by Region (2019-2024)
2.2.3 Neuromyelitis Optica Spectrum Disorder (NMOSD) Forecasted Market Size by Region (2025-2030)
2.3 Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Dynamics
2.3.1 Neuromyelitis Optica Spectrum Disorder (NMOSD) Industry Trends
2.3.2 Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Drivers
2.3.3 Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Challenges
2.3.4 Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Neuromyelitis Optica Spectrum Disorder (NMOSD) Players by Revenue
3.1.1 Global Top Neuromyelitis Optica Spectrum Disorder (NMOSD) Players by Revenue (2019-2024)
3.1.2 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue Market Share by Players (2019-2024)
3.2 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue
3.4 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Concentration Ratio
3.4.1 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue in 2023
3.5 Neuromyelitis Optica Spectrum Disorder (NMOSD) Key Players Head office and Area Served
3.6 Key Players Neuromyelitis Optica Spectrum Disorder (NMOSD) Product Solution and Service
3.7 Date of Enter into Neuromyelitis Optica Spectrum Disorder (NMOSD) Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Neuromyelitis Optica Spectrum Disorder (NMOSD) Breakdown Data by Type
4.1 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Historic Market Size by Type (2019-2024)
4.2 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Forecasted Market Size by Type (2025-2030)
5 Neuromyelitis Optica Spectrum Disorder (NMOSD) Breakdown Data by Application
5.1 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Historic Market Size by Application (2019-2024)
5.2 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size (2019-2030)
6.2 North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Country (2019-2024)
6.4 North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size (2019-2030)
7.2 Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Country (2019-2024)
7.4 Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size (2019-2030)
8.2 Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Region (2019-2024)
8.4 Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size (2019-2030)
9.2 Latin America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Country (2019-2024)
9.4 Latin America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size (2019-2030)
10.2 Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Country (2019-2024)
10.4 Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 F. Hoffmann-La Roche Ltd
11.1.1 F. Hoffmann-La Roche Ltd Company Detail
11.1.2 F. Hoffmann-La Roche Ltd Business Overview
11.1.3 F. Hoffmann-La Roche Ltd Neuromyelitis Optica Spectrum Disorder (NMOSD) Introduction
11.1.4 F. Hoffmann-La Roche Ltd Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2019-2024)
11.1.5 F. Hoffmann-La Roche Ltd Recent Development
11.2 Alexion Pharmaceuticals
11.2.1 Alexion Pharmaceuticals Company Detail
11.2.2 Alexion Pharmaceuticals Business Overview
11.2.3 Alexion Pharmaceuticals Neuromyelitis Optica Spectrum Disorder (NMOSD) Introduction
11.2.4 Alexion Pharmaceuticals Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2019-2024)
11.2.5 Alexion Pharmaceuticals Recent Development
11.3 RemeGen
11.3.1 RemeGen Company Detail
11.3.2 RemeGen Business Overview
11.3.3 RemeGen Neuromyelitis Optica Spectrum Disorder (NMOSD) Introduction
11.3.4 RemeGen Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2019-2024)
11.3.5 RemeGen Recent Development
11.4 Nihon Pharmaceutical
11.4.1 Nihon Pharmaceutical Company Detail
11.4.2 Nihon Pharmaceutical Business Overview
11.4.3 Nihon Pharmaceutical Neuromyelitis Optica Spectrum Disorder (NMOSD) Introduction
11.4.4 Nihon Pharmaceutical Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2019-2024)
11.4.5 Nihon Pharmaceutical Recent Development
11.5 Harbour BioMed
11.5.1 Harbour BioMed Company Detail
11.5.2 Harbour BioMed Business Overview
11.5.3 Harbour BioMed Neuromyelitis Optica Spectrum Disorder (NMOSD) Introduction
11.5.4 Harbour BioMed Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2019-2024)
11.5.5 Harbour BioMed Recent Development
11.6 Lundbeck
11.6.1 Lundbeck Company Detail
11.6.2 Lundbeck Business Overview
11.6.3 Lundbeck Neuromyelitis Optica Spectrum Disorder (NMOSD) Introduction
11.6.4 Lundbeck Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2019-2024)
11.6.5 Lundbeck Recent Development
11.7 Bionure
11.7.1 Bionure Company Detail
11.7.2 Bionure Business Overview
11.7.3 Bionure Neuromyelitis Optica Spectrum Disorder (NMOSD) Introduction
11.7.4 Bionure Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2019-2024)
11.7.5 Bionure Recent Development
11.8 Opexa Therapeutics
11.8.1 Opexa Therapeutics Company Detail
11.8.2 Opexa Therapeutics Business Overview
11.8.3 Opexa Therapeutics Neuromyelitis Optica Spectrum Disorder (NMOSD) Introduction
11.8.4 Opexa Therapeutics Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2019-2024)
11.8.5 Opexa Therapeutics Recent Development
11.9 TG Therapeutics
11.9.1 TG Therapeutics Company Detail
11.9.2 TG Therapeutics Business Overview
11.9.3 TG Therapeutics Neuromyelitis Optica Spectrum Disorder (NMOSD) Introduction
11.9.4 TG Therapeutics Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2019-2024)
11.9.5 TG Therapeutics Recent Development
11.10 Bio-Thera Solutions
11.10.1 Bio-Thera Solutions Company Detail
11.10.2 Bio-Thera Solutions Business Overview
11.10.3 Bio-Thera Solutions Neuromyelitis Optica Spectrum Disorder (NMOSD) Introduction
11.10.4 Bio-Thera Solutions Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2019-2024)
11.10.5 Bio-Thera Solutions Recent Development
11.11 Boston Pharmaceuticals
11.11.1 Boston Pharmaceuticals Company Detail
11.11.2 Boston Pharmaceuticals Business Overview
11.11.3 Boston Pharmaceuticals Neuromyelitis Optica Spectrum Disorder (NMOSD) Introduction
11.11.4 Boston Pharmaceuticals Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2019-2024)
11.11.5 Boston Pharmaceuticals Recent Development
11.12 Cour Pharmaceutical
11.12.1 Cour Pharmaceutical Company Detail
11.12.2 Cour Pharmaceutical Business Overview
11.12.3 Cour Pharmaceutical Neuromyelitis Optica Spectrum Disorder (NMOSD) Introduction
11.12.4 Cour Pharmaceutical Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2019-2024)
11.12.5 Cour Pharmaceutical Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesList of Tables
Table 1. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Intravenous
Table 3. Key Players of Oral
Table 4. Key Players of Subcutaneous
Table 5. Key Players of Others
Table 6. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 7. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 8. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Region (2019-2024) & (US$ Million)
Table 9. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share by Region (2019-2024)
Table 10. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 11. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share by Region (2025-2030)
Table 12. Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Trends
Table 13. Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Drivers
Table 14. Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Challenges
Table 15. Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Restraints
Table 16. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue by Players (2019-2024) & (US$ Million)
Table 17. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share by Players (2019-2024)
Table 18. Global Top Neuromyelitis Optica Spectrum Disorder (NMOSD) Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) as of 2023)
Table 19. Ranking of Global Top Neuromyelitis Optica Spectrum Disorder (NMOSD) Companies by Revenue (US$ Million) in 2023
Table 20. Global 5 Largest Players Market Share by Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue (CR5 and HHI) & (2019-2024)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Neuromyelitis Optica Spectrum Disorder (NMOSD) Product Solution and Service
Table 23. Date of Enter into Neuromyelitis Optica Spectrum Disorder (NMOSD) Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type (2019-2024) & (US$ Million)
Table 26. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue Market Share by Type (2019-2024)
Table 27. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 28. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue Market Share by Type (2025-2030)
Table 29. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application (2019-2024) & (US$ Million)
Table 30. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue Market Share by Application (2019-2024)
Table 31. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 32. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue Market Share by Application (2025-2030)
Table 33. North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 34. North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Country (2019-2024) & (US$ Million)
Table 35. North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Country (2025-2030) & (US$ Million)
Table 36. Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 37. Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Country (2019-2024) & (US$ Million)
Table 38. Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Country (2025-2030) & (US$ Million)
Table 39. Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 40. Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Region (2019-2024) & (US$ Million)
Table 41. Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Region (2025-2030) & (US$ Million)
Table 42. Latin America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 43. Latin America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Country (2019-2024) & (US$ Million)
Table 44. Latin America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Country (2025-2030) & (US$ Million)
Table 45. Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 46. Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Country (2019-2024) & (US$ Million)
Table 47. Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Country (2025-2030) & (US$ Million)
Table 48. F. Hoffmann-La Roche Ltd Company Detail
Table 49. F. Hoffmann-La Roche Ltd Business Overview
Table 50. F. Hoffmann-La Roche Ltd Neuromyelitis Optica Spectrum Disorder (NMOSD) Product
Table 51. F. Hoffmann-La Roche Ltd Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2019-2024) & (US$ Million)
Table 52. F. Hoffmann-La Roche Ltd Recent Development
Table 53. Alexion Pharmaceuticals Company Detail
Table 54. Alexion Pharmaceuticals Business Overview
Table 55. Alexion Pharmaceuticals Neuromyelitis Optica Spectrum Disorder (NMOSD) Product
Table 56. Alexion Pharmaceuticals Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2019-2024) & (US$ Million)
Table 57. Alexion Pharmaceuticals Recent Development
Table 58. RemeGen Company Detail
Table 59. RemeGen Business Overview
Table 60. RemeGen Neuromyelitis Optica Spectrum Disorder (NMOSD) Product
Table 61. RemeGen Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2019-2024) & (US$ Million)
Table 62. RemeGen Recent Development
Table 63. Nihon Pharmaceutical Company Detail
Table 64. Nihon Pharmaceutical Business Overview
Table 65. Nihon Pharmaceutical Neuromyelitis Optica Spectrum Disorder (NMOSD) Product
Table 66. Nihon Pharmaceutical Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2019-2024) & (US$ Million)
Table 67. Nihon Pharmaceutical Recent Development
Table 68. Harbour BioMed Company Detail
Table 69. Harbour BioMed Business Overview
Table 70. Harbour BioMed Neuromyelitis Optica Spectrum Disorder (NMOSD) Product
Table 71. Harbour BioMed Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2019-2024) & (US$ Million)
Table 72. Harbour BioMed Recent Development
Table 73. Lundbeck Company Detail
Table 74. Lundbeck Business Overview
Table 75. Lundbeck Neuromyelitis Optica Spectrum Disorder (NMOSD) Product
Table 76. Lundbeck Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2019-2024) & (US$ Million)
Table 77. Lundbeck Recent Development
Table 78. Bionure Company Detail
Table 79. Bionure Business Overview
Table 80. Bionure Neuromyelitis Optica Spectrum Disorder (NMOSD) Product
Table 81. Bionure Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2019-2024) & (US$ Million)
Table 82. Bionure Recent Development
Table 83. Opexa Therapeutics Company Detail
Table 84. Opexa Therapeutics Business Overview
Table 85. Opexa Therapeutics Neuromyelitis Optica Spectrum Disorder (NMOSD) Product
Table 86. Opexa Therapeutics Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2019-2024) & (US$ Million)
Table 87. Opexa Therapeutics Recent Development
Table 88. TG Therapeutics Company Detail
Table 89. TG Therapeutics Business Overview
Table 90. TG Therapeutics Neuromyelitis Optica Spectrum Disorder (NMOSD) Product
Table 91. TG Therapeutics Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2019-2024) & (US$ Million)
Table 92. TG Therapeutics Recent Development
Table 93. Bio-Thera Solutions Company Detail
Table 94. Bio-Thera Solutions Business Overview
Table 95. Bio-Thera Solutions Neuromyelitis Optica Spectrum Disorder (NMOSD) Product
Table 96. Bio-Thera Solutions Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2019-2024) & (US$ Million)
Table 97. Bio-Thera Solutions Recent Development
Table 98. Boston Pharmaceuticals Company Detail
Table 99. Boston Pharmaceuticals Business Overview
Table 100. Boston Pharmaceuticals Neuromyelitis Optica Spectrum Disorder (NMOSD) Product
Table 101. Boston Pharmaceuticals Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2019-2024) & (US$ Million)
Table 102. Boston Pharmaceuticals Recent Development
Table 103. Cour Pharmaceutical Company Detail
Table 104. Cour Pharmaceutical Business Overview
Table 105. Cour Pharmaceutical Neuromyelitis Optica Spectrum Disorder (NMOSD) Product
Table 106. Cour Pharmaceutical Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2019-2024) & (US$ Million)
Table 107. Cour Pharmaceutical Recent Development
Table 108. Research Programs/Design for This Report
Table 109. Key Data Information from Secondary Sources
Table 110. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share by Type: 2023 VS 2030
Figure 3. Intravenous Features
Figure 4. Oral Features
Figure 5. Subcutaneous Features
Figure 6. Others Features
Figure 7. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 8. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share by Application: 2023 VS 2030
Figure 9. Hospital Case Studies
Figure 10. Clinic Case Studies
Figure 11. Others Case Studies
Figure 12. Neuromyelitis Optica Spectrum Disorder (NMOSD) Report Years Considered
Figure 13. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 14. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 15. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share by Region: 2023 VS 2030
Figure 16. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share by Players in 2023
Figure 17. Global Top Neuromyelitis Optica Spectrum Disorder (NMOSD) Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) as of 2023)
Figure 18. The Top 10 and 5 Players Market Share by Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue in 2023
Figure 19. North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 20. North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share by Country (2019-2030)
Figure 21. United States Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 22. Canada Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 23. Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 24. Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share by Country (2019-2030)
Figure 25. Germany Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. France Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. U.K. Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. Italy Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Russia Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Nordic Countries Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share by Region (2019-2030)
Figure 33. China Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. Japan Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. South Korea Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. Southeast Asia Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. India Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. Australia Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Latin America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. Latin America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share by Country (2019-2030)
Figure 41. Mexico Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Brazil Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share by Country (2019-2030)
Figure 45. Turkey Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 46. Saudi Arabia Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 47. F. Hoffmann-La Roche Ltd Revenue Growth Rate in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2019-2024)
Figure 48. Alexion Pharmaceuticals Revenue Growth Rate in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2019-2024)
Figure 49. RemeGen Revenue Growth Rate in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2019-2024)
Figure 50. Nihon Pharmaceutical Revenue Growth Rate in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2019-2024)
Figure 51. Harbour BioMed Revenue Growth Rate in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2019-2024)
Figure 52. Lundbeck Revenue Growth Rate in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2019-2024)
Figure 53. Bionure Revenue Growth Rate in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2019-2024)
Figure 54. Opexa Therapeutics Revenue Growth Rate in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2019-2024)
Figure 55. TG Therapeutics Revenue Growth Rate in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2019-2024)
Figure 56. Bio-Thera Solutions Revenue Growth Rate in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2019-2024)
Figure 57. Boston Pharmaceuticals Revenue Growth Rate in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2019-2024)
Figure 58. Cour Pharmaceutical Revenue Growth Rate in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2019-2024)
Figure 59. Bottom-up and Top-down Approaches for This Report
Figure 60. Data Triangulation
Figure 61. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
